Sanjiv Patel Relay Therapeutics, Inc. (RLAY) insider trading activity

Sanjiv Patel is President and CEO of Relay Therapeutics, Inc.. Currently has a direct ownership of 766,130 shares of RLAY, which is worth approximately $5.82 Million. The most recent transaction as insider was on Oct 12, 2022, when has been sold 14,000 shares (Common Stock) at a price of $21.18 per share, resulting in proceeds of $296,520. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 766K

0.28% 3M change

45996.87% 12M change

Total Value Held $5.82 Million

Sanjiv Patel Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Oct 12 2022	SELL Open market or private sale	$296,520 $21.18 p/Share	14,000 Reduced 5.21%	254,554 Common Stock
Oct 12 2022	BUY Exercise of conversion of derivative security	$57,680 $4.12 p/Share	14,000 Added 4.95%	268,554 Common Stock
Oct 11 2022	SELL Open market or private sale	$299,040 $21.36 p/Share	14,000 Reduced 5.21%	254,554 Common Stock
Oct 11 2022	BUY Exercise of conversion of derivative security	$57,680 $4.12 p/Share	14,000 Added 4.95%	268,554 Common Stock
Sep 15 2022	SELL Open market or private sale	$333,200 $23.8 p/Share	14,000 Reduced 5.21%	254,554 Common Stock
Sep 15 2022	BUY Exercise of conversion of derivative security	$57,680 $4.12 p/Share	14,000 Added 4.95%	268,554 Common Stock
Sep 14 2022	SELL Open market or private sale	$328,580 $23.47 p/Share	14,000 Reduced 5.21%	254,554 Common Stock
Sep 14 2022	BUY Exercise of conversion of derivative security	$57,680 $4.12 p/Share	14,000 Added 4.95%	268,554 Common Stock
Sep 13 2022	SELL Open market or private sale	$356,300 $25.45 p/Share	14,000 Reduced 5.21%	254,554 Common Stock
Sep 13 2022	BUY Exercise of conversion of derivative security	$57,680 $4.12 p/Share	14,000 Added 4.95%	268,554 Common Stock
Jun 30 2022	BUY Grant, award, or other acquisition	$11,591 $14.24 p/Share	814 Added 0.32%	254,554 Common Stock
Apr 14 2022	SELL Open market or private sale	$854,280 $30.51 p/Share	28,000 Reduced 9.94%	253,740 Common Stock
Apr 14 2022	BUY Exercise of conversion of derivative security	$128,240 $4.58 p/Share	28,000 Added 9.47%	267,740 Common Stock
Apr 13 2022	SELL Open market or private sale	$894,600 $31.95 p/Share	28,000 Reduced 9.94%	253,740 Common Stock
Apr 13 2022	BUY Exercise of conversion of derivative security	$128,240 $4.58 p/Share	28,000 Added 9.47%	267,740 Common Stock
Apr 12 2022	SELL Open market or private sale	$890,400 $31.8 p/Share	28,000 Reduced 9.94%	253,740 Common Stock
Apr 12 2022	BUY Exercise of conversion of derivative security	$115,360 $4.12 p/Share	28,000 Added 9.04%	281,740 Common Stock
Dec 31 2021	BUY Grant, award, or other acquisition	$17,174 $26.1 p/Share	658 Added 0.26%	253,740 Common Stock
Feb 16 2021	SELL Bona fide gift	-	150,000 Reduced 37.21%	253,082 Common Stock

Also insider at

PRTA

PROTHENA CORP PUBLIC LTD CO Healthcare

Sanjiv Patel

President and CEO

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RLAY shares.

Notify only if

Value

Insider Trading

Get notified when an Relay Therapeutics, Inc. insider buys or sells RLAY shares.

Notify only if

Operation

Value

Type

News

Receive news related to Relay Therapeutics, Inc.

Track Activities on RLAY

Account